nach oben

Erschienen in:

05.01.2022 | Review

Is autosomal dominant polycystic kidney disease an early sweet disease?

verfasst von: Angélique Dachy, Jean-Paul Decuypere, Rudi Vennekens, François Jouret, Djalila Mekahli

Erschienen in: Pediatric Nephrology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

The clinical course of autosomal dominant polycystic kidney disease (ADPKD) starts in childhood. Evidence of the beneficial impact of early nephron-protective strategies and lifestyle modifications on ADPKD prognosis is accumulating. Recent studies have described the association of overweight and obesity with rapid disease progression in adults with ADPKD. Moreover, defective glucose metabolism and metabolic reprogramming have been reported in distinct ADPKD models highlighting these pathways as potential therapeutic targets in ADPKD. Several “metabolic” approaches are currently under evaluation in adults, including ketogenic diet, food restriction, and metformin therapy. No data are available on the impact of these approaches in childhood thus far. Yet, according to World Health Organization (WHO), we are currently facing a childhood obesity crisis with an increased prevalence of overweight/obesity in the pediatric population associated with a cardio-metabolic risk profile. The present review summarizes the knowledge about the role of glucose metabolism in the pathophysiology of ADPKD and underscores the possible harm of overweight and obesity in ADPKD especially in terms of long-term cardiovascular outcomes and renal prognosis.

Rowe I, Boletta A (2014) Defective metabolism in polycystic kidney disease: potential for therapy and open questions. Nephrol Dial Transplant 29:1480–1486. https://doi.org/10.1093/ndt/gft521CrossRefPubMed

Rowe I, Chiaravalli M, Mannella V, Ulisse V et al (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19:488–493. https://doi.org/10.1038/nm.3092CrossRefPubMedPubMedCentral

Nowak KL, Hopp K (2020) Metabolic reprogramming in autosomal dominant polycystic kidney disease evidence and therapeutic potential. Clin J Am Soc Nephrol 15:577–584. https://doi.org/10.2215/CJN.13291019CrossRefPubMedPubMedCentral

Podrini C, Rowe I, Pagliarini R, Costa ASH et al (2018) Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun Biol 1:194. https://doi.org/10.1038/s42003-018-0200-xCrossRefPubMedPubMedCentral

Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Physiol 310:F726–F731. https://doi.org/10.1152/ajprenal.00551.2015CrossRef

Warner G, Hein KZ, Nin V, Edwards M et al (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27:1437–1447. https://doi.org/10.1681/ASN.2015020132CrossRefPubMed

Torres JA, Kruger SL, Broderick C, Amarlkhagva T et al (2019) Ketosis ameliorates renal cyst growth in polycystic kidney disease. Cell Metab 30:1007–1023. https://doi.org/10.1016/j.cmet.2019.09.012CrossRefPubMedPubMedCentral

Takiar V, Nishio S, Seo-Mayer P, King JD Jr et al (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108:2462–2467. https://doi.org/10.1073/pnas.1011498108CrossRefPubMedPubMedCentral

Chang MY, Ma TL, Hung CC, Tian YC et al (2017) Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci Rep 7:7161. https://doi.org/10.1038/s41598-017-07300-xCrossRefPubMedPubMedCentral

10.

Perrone RD, Abebe KZ, Watnick T, Althouse AD et al (2021) Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int 100:684–696. https://doi.org/10.1016/j.kint.2021.06.013CrossRefPubMed

11.

Brosnahan GM, Wang W, Gitomer B, Struemph T et al (2021) Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study. Am J Kidney Dis 12:S0272-6386(21)00790-3. https://doi.org/10.1053/j.ajkd.2021.06.026

12.

Wang X, Zhang S, Liu Y, Spichtig D et al (2013) Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney Int 84:962–968. https://doi.org/10.1038/ki.2013.199CrossRefPubMed

13.

Kapoor S, Rodriguez D, Riwanto M, Edenhofer I et al (2015) Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS ONE 10:e0125603. https://doi.org/10.1371/journal.pone.0125603CrossRefPubMedPubMedCentral

14.

Rodriguez D, Kapoor S, Edenhofer I, Segerer S et al (2015) Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease. Kidney Blood Press Res 40:638–647. https://doi.org/10.1159/000368540CrossRefPubMed

15.

Leonhard WN, Song X, Kanhai AA, Iliuta IA et al (2019) Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 47:436–445. https://doi.org/10.1016/j.ebiom.2019.08.041CrossRefPubMedPubMedCentral

16.

Fliszkiewicz M, Niemczyk M, Kulesza A, Łabuś A, Pączek L (2019) Glucose and lipid metabolism abnormalities among patients with autosomal dominant polycystic kidney disease. Kidney Blood Press Res 44:1416–1422. https://doi.org/10.1159/000503423CrossRefPubMed

17.

Pietrzak-Nowacka M, Safranow K, Byra E, Nowosiad M, Marchelek-Myśliwiec M, Ciechanowski K (2010) Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease. Scand J Clin Lab Invest 70:561–567. https://doi.org/10.3109/00365513.2010.527012CrossRefPubMed

18.

Nowak KL, You Z, Gitomer B, Brosnahan G et al (2018) Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol 29:571–578. https://doi.org/10.1681/ASN.2017070819CrossRefPubMed

19.

Baliga MM, Klawitter J, Christians U, Hopp K et al (2021) Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep 11:6629. https://doi.org/10.1038/s41598-021-84609-8CrossRefPubMedPubMedCentral

20.

Yun H-R, Kim H, Park JT, Chang TI et al (2018) Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis 72:400–410. https://doi.org/10.1053/j.ajkd.2018.02.362CrossRefPubMed

21.

Spoto B, Pisano A, Zoccali C (2016) Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol 311:F1087–F1108. https://doi.org/10.1152/ajprenal.00340.2016CrossRefPubMed

22.

Lalan S, Jiang S, Ng DK, Kupferman F et al (2018) Cardiometabolic risk factors, metabolic syndrome, and chronic kidney disease progression in children. J Pediatr 202:163–170. https://doi.org/10.1016/j.jpeds.2018.06.007CrossRefPubMedPubMedCentral

23.

Foster MC, Hwang S-J, Larson MG, Lichtman JH et al (2008) Overweight, obesity, and the development of stage 3 CKD: the Framingham heart study. Am J kidney Dis 52:39–48. https://doi.org/10.1053/j.ajkd.2008.03.003CrossRefPubMedPubMedCentral

24.

Spinelli A, Buoncristiano M, Kovacs VA, Yngve A et al (2019) Prevalence of severe obesity among primary school children in 21 European countries. Obes Facts 12:244–258. https://doi.org/10.1159/000500436CrossRefPubMedPubMedCentral

25.

Sorof JM, Poffenbarger T, Franco K, Bernard L et al (2002) Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr 140:660–666. https://doi.org/10.1067/mpd.2002.125228CrossRefPubMed

26.

Sinha R, Fisch G, Teague B, Tamborlane WV et al (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802–810. https://doi.org/10.1056/NEJMoa012578CrossRefPubMed

27.

Shaw J (2007) Epidemiology of childhood type 2 diabetes and obesity. Pediatr Diabetes 8(Suppl 9):7–15. https://doi.org/10.1111/j.1399-5448.2007.00329.xCrossRefPubMed

28.

Skinner AC, Perrin EM, Moss LA, Skelton JA (2015) Cardiometabolic risks and severity of obesity in children and young adults. N Engl J Med 373:1307–1317. https://doi.org/10.1056/NEJMoa1502821CrossRefPubMed

29.

Baker JL, Olsen LW, Sørensen TIA (2007) Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 357:2329–2337. https://doi.org/10.1056/NEJMoa072515CrossRefPubMedPubMedCentral

30.

Wilson PWF, D’Agostino RB, Sullivan L, Parise H, Kannel WB (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867–1872. https://doi.org/10.1001/archinte.162.16.1867CrossRefPubMed

31.

Yajnik CS, Katre PA, Joshi SM, Kumaran K et al (2015) Higher glucose, insulin and insulin resistance (HOMA-IR) in childhood predict adverse cardiovascular risk in early adulthood: the Pune children’s study. Diabetologia 58:1626–1636. https://doi.org/10.1007/s00125-015-3602-zCrossRefPubMedPubMedCentral

32.

Nowak KL, Steele C, Gitomer B, Wang W et al (2021) Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol 16:908–915. https://doi.org/10.2215/CJN.16871020CrossRefPubMedPubMedCentral

33.

Vareesangthip K, Tong P, Wilkinson R, Thomas TH (1997) Insulin resistance in adult polycystic kidney disease. Kidney Int 52:503–508. https://doi.org/10.1038/ki.1997.360CrossRefPubMed

34.

Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A et al (1998) Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53:1343–1347. https://doi.org/10.1046/j.1523-1755.1998.00898.xCrossRefPubMed

35.

Turkmen K, Tufan F, Selçuk E, Akpınar T, Oflaz H, Ecder T (2013) Neutrophil-to-lymphocyte ratio, insulin resistance, and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Indian J Nephrol 23:34–40. https://doi.org/10.4103/0971-4065.107195CrossRefPubMedPubMedCentral

36.

Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M (2011) Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6:7–13. https://doi.org/10.2215/CJN.04140510CrossRefPubMedPubMedCentral

37.

DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 6:E214. https://doi.org/10.1152/ajpendo.1979.237.3.e214CrossRef

38.

Hamer RA, Chow CL, Ong ACM, McKane WS (2007) Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 83:36–40. https://doi.org/10.1097/01.tp.0000248759.37146.3dCrossRefPubMed

39.

Caillard S, Eprinchard L, Perrin P, Braun L et al (2011) Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 91:757–764. https://doi.org/10.1097/TP.0b013e31820f0877CrossRefPubMed

40.

de Mattos AM, Olyaei AJ, Prather JC, Golconda MS et al (2005) Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 67:714–720. https://doi.org/10.1111/j.1523-1755.2005.67132.xCrossRefPubMed

41.

Reed B, Helal I, McFann K, Wang W et al (2011) The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27:2862–2865. https://doi.org/10.1093/ndt/gfr744CrossRefPubMedPubMedCentral

42.

Kuo IY, Chapman AB (2020) Polycystins, ADPKD, and cardiovascular disease. Kidney Int reports 5:396–406. https://doi.org/10.1016/j.ekir.2019.12.007CrossRef

43.

Major RW, Cheng MRI, Grant RA, Shantikumar S et al (2018) Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE 13:e0192895. https://doi.org/10.1371/journal.pone.0192895CrossRefPubMedPubMedCentral

44.

Sans L, Pascual J, Radosevic A, Quintian C et al (2016) Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients. Medicine (Baltimore) 95:e5595. https://doi.org/10.1097/MD.0000000000005595CrossRef

45.

Lai S, Mastroluca D, Matino S, Panebianco V et al (2017) Early markers of cardiovascular risk in autosomal dominant polycystic kidney disease. Kidney Blood Press Res 42:1290–1302. https://doi.org/10.1159/000486011CrossRefPubMed

46.

Gorriz JL, Arroyo D, D’Marco L, Torra R et al (2021) Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease. BMC Nephrol 22:110. https://doi.org/10.1186/s12882-021-02313-1CrossRefPubMedPubMedCentral

47.

Nowak KL, Murray K, You Z, Gitomer B et al (2021) Pain and obesity in autosomal dominant polycystic kidney disease: a post hoc analysis of the halt progression of polycystic kidney disease (HALT-PKD) studies. Kidney Med 3:536-545.e1. https://doi.org/10.1016/j.xkme.2021.03.004CrossRefPubMedPubMedCentral

48.

Bajwa ZH, Gupta S, Warfield CA, Steinman TI (2001) Pain management in polycystic kidney disease. Kidney Int 60:1631–1644. https://doi.org/10.1046/j.1523-1755.2001.00985.xCrossRefPubMed

49.

World Health Organization (2017) Tenfold increase in childhood and adolescent obesity in four decades: new study by Imperial College London and WHO. In: Available online. https://www.who.int/news/item/11-10-2017-. Accessed 3 Jun 2021

50.

Franks PW, Hanson RL, Knowler WC, Sievers ML et al (2010) Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 362:485–493. https://doi.org/10.1056/NEJMoa0904130CrossRefPubMedPubMedCentral

51.

Whaley-Connell A, Sowers JR (2017) Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiorenal Med 8:41–49. https://doi.org/10.1159/000479801CrossRefPubMedPubMedCentral

52.

Helal I, Reed B, Mcfann K, Yan XD et al (2011) Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2439–2443. https://doi.org/10.2215/CJN.01010211CrossRefPubMedPubMedCentral

53.

Chagnac A, Weinstein T, Korzets A, Ramadan E et al (2000) Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278:F817-822. https://doi.org/10.1152/ajprenal.2000.278.5.F817CrossRefPubMed

54.

Kahveci AS, Barnatan TT, Kahveci A, Adrian AE et al (2020) Oxidative stress and mitochondrial abnormalities contribute to decreased endothelial nitric oxide synthase expression and renal disease progression in early experimental polycystic kidney disease. Int J Mol Sci 21:1994. https://doi.org/10.3390/ijms21061994CrossRefPubMedCentral

55.

Murphy MO, Huang H, Bauer JA, Schadler A et al (2021) Impact of pediatric obesity on diurnal blood pressure assessment and cardiovascular risk markers. Front Pediatr 9:123. https://doi.org/10.3389/fped.2021.596142CrossRef

56.

Litwin M, Kułaga Z (2021) Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol 36:825–837. https://doi.org/10.1007/s00467-020-04579-3CrossRefPubMed

57.

Marlais M, Cuthell O, Langan D, Dudley J et al (2016) Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. Arch Dis Child 101:1142–1147. https://doi.org/10.1136/archdischild-2015-310221CrossRefPubMed

58.

Massella L, Mekahli D, Paripović D, Prikhodina L et al (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:874–883. https://doi.org/10.2215/CJN.11401017CrossRefPubMedPubMedCentral

59.

Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA (2001) Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59:1654–1662. https://doi.org/10.1046/j.1523-1755.2001.0590051654.xCrossRefPubMed

60.

Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192–1196. https://doi.org/10.1038/ki.2008.397CrossRefPubMedPubMedCentral

61.

Mastrangelo A, Martos-Moreno GÁ, García A, Barrios V et al (2016) Insulin resistance in prepubertal obese children correlates with sex-dependent early onset metabolomic alterations. Int J Obes (Lond) 40:1494–1502. https://doi.org/10.1038/ijo.2016.92CrossRef

62.

Kwaifa IK, Bahari H, Yong YK, Noor SM (2020) Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. Biomolecules 10:291. https://doi.org/10.3390/biom10020291CrossRefPubMedCentral

63.

Chiaravalli M, Rowe I, Mannella V, Quilici G et al (2016) 2-Deoxy-D-glucose ameliorates PKD progression. J Am Soc Nephrol 27:1958–1969. https://doi.org/10.1681/ASN.2015030231CrossRefPubMed

64.

Riwanto M, Kapoor S, Rodriguez D, Edenhofer I et al (2016) Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. PLoS ONE 11:e0146654. https://doi.org/10.1371/journal.pone.0146654CrossRefPubMedPubMedCentral

65.

Grahammer F, Ramakrishnan SK, Rinschen MM, Larionov AA et al (2017) mTOR regulates endocytosis and nutrient transport in proximal tubular cells. J Am Soc Nephrol 28:230–241. https://doi.org/10.1681/ASN.2015111224CrossRefPubMed

66.

Zhang H, Kong W-J, Shan Y-Q, Song D-Q et al (2010) Protein kinase D activation stimulates the transcription of the insulin receptor gene. Mol Cell Endocrinol 330:25–32. https://doi.org/10.1016/j.mce.2010.07.022CrossRefPubMed

67.

Khan S, Ferdaoussi M, Bautista A, Bergeron V et al (2019) A role for PKD1 in insulin secretion downstream of P2Y1 receptor activation in mouse and human islets. Physiol Rep 7:e14250. https://doi.org/10.14814/phy2.14250CrossRefPubMedPubMedCentral

68.

Kashyap S, Hein KZ, Chini CC, Lika J et al (2020) Metalloproteinase PAPP - a regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. JCI Insight 5:e135700. https://doi.org/10.1172/jci.insight.135700CrossRefPubMedCentral

69.

Kashyap S, Zeidler JD, Chini CCS, Chini EN (2020) Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease. Cell Signal 73:109698. https://doi.org/10.1016/j.cellsig.2020.109698CrossRefPubMedPubMedCentral

70.

Ramalingam H, Kashyap S, Cobo-Stark P, Flaten A et al (2021) A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease. Cell Metab 33:1234-1247.e7. https://doi.org/10.1016/j.cmet.2021.03.024CrossRefPubMedPubMedCentral

71.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403. https://doi.org/10.1056/NEJMoa012512CrossRefPubMed

72.

Seifarth C, Schehler B, Schneider HJ (2013) Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 121:27–31. https://doi.org/10.1055/s-0032-1327734CrossRefPubMed

73.

Soliman A, DeSanctis V, Alaaraj N, Hamed N (2020) The clinical application of metformin in children and adolescents: a short update. Acta Biomed 91:e2020086. https://doi.org/10.23750/abm.v91i3.10127CrossRefPubMedPubMedCentral

74.

Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB (2021) Efficacy and safety of metformin for obesity: a systematic review. Pediatrics 147:e20201610. https://doi.org/10.1542/peds.2020-1610

75.

Bassols J, Martínez-Calcerrada J-M, Osiniri I, Díaz-Roldán F et al (2019) Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: a pilot study. PLoS ONE 14:e0226303. https://doi.org/10.1371/journal.pone.0226303CrossRefPubMedPubMedCentral

76.

Bjornstad P, Schäfer M, Truong U, Cree-Green M et al (2018) Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation 138:2895–2907. https://doi.org/10.1161/CIRCULATIONAHA.118.035525CrossRefPubMedPubMedCentral

77.

Park MH, Kinra S, Ward KJ, White B, Viner RM (2009) Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 32:1743–1745. https://doi.org/10.2337/dc09-0258CrossRefPubMedPubMedCentral

78.

Kendall D, Vail A, Amin R, Barrett T et al (2013) Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 98:322–329. https://doi.org/10.1210/jc.2012-2710CrossRefPubMed

79.

De Broe ME, Jouret F (2020) Does metformin do more benefit or harm in chronic kidney disease patients? Kidney Int 98:1098–1101. https://doi.org/10.1016/j.kint.2020.04.059CrossRefPubMed

80.

Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB et al (2017) Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166:191–200. https://doi.org/10.7326/M16-1901CrossRefPubMedPubMedCentral

81.

Ong ACM, Gansevoort RT (2021) TAMEing ADPKD with metformin: safe and effective? Kidney Int 100:513–515. https://doi.org/10.1016/j.kint.2021.07.021CrossRefPubMed

82.

Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94:26–39. https://doi.org/10.1016/j.kint.2017.12.027CrossRefPubMed

83.

Perkovic V, Jardine MJ, Neal B, Bompoint S et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744CrossRefPubMed

84.

Levin A, Perkovic V, Wheeler DC, Hantel S et al (2020) Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial. Clin J Am Soc Nephrol 15:1433–1444. https://doi.org/10.2215/CJN.14901219CrossRefPubMedPubMedCentral

Titel: Is autosomal dominant polycystic kidney disease an early sweet disease?
verfasst von: Angélique Dachy
Jean-Paul Decuypere
Rudi Vennekens
François Jouret
Djalila Mekahli
Publikationsdatum: 05.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 9/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-021-05406-z

Major adverse kidney events after acute kidney injury in the pediatric intensive care unit: a propensity score–matched cohort study

Original Article

Defining kidney outcomes in children with acute lymphoblastic leukemia in the modern era

Original Article

Female adolescent with recurrent anemia and thrombocytopenia: Questions

Clinical Quiz

Metabolic alkalosis in peritoneal dialysis — beyond the obvious: Questions

Clinical Quiz

Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipients

Original Article

Rickets guidance: part I—diagnostic workup

Open Access
Educational Review

Neu im Fachgebiet Pädiatrie

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

09.01.2025
Gestationsdiabetes
Nachrichten

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is autosomal dominant polycystic kidney disease an early sweet disease?

Abstract

Weitere Artikel der Ausgabe 9/2022

Major adverse kidney events after acute kidney injury in the pediatric intensive care unit: a propensity score–matched cohort study

Defining kidney outcomes in children with acute lymphoblastic leukemia in the modern era

Female adolescent with recurrent anemia and thrombocytopenia: Questions

Metabolic alkalosis in peritoneal dialysis — beyond the obvious: Questions

Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipients

Rickets guidance: part I—diagnostic workup

Neu im Fachgebiet Pädiatrie

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten